reboxetine has been researched along with sertraline in 14 studies
| Studies (reboxetine) | Trials (reboxetine) | Recent Studies (post-2010) (reboxetine) | Studies (sertraline) | Trials (sertraline) | Recent Studies (post-2010) (sertraline) |
|---|---|---|---|---|---|
| 626 | 193 | 184 | 3,480 | 1,028 | 1,329 |
| Protein | Taxonomy | reboxetine (IC50) | sertraline (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 1.083 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.9848 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 2.7675 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 2.6309 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.8 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.5073 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.2888 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 1.4 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 1.2882 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 8.3173 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.1814 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 4.477 | |
| D | Rattus norvegicus (Norway rat) | 0.26 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.26 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.8783 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 0.825 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.26 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 2.7409 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 1.083 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.26 | |
| 3-oxo-5-alpha-steroid 4-dehydrogenase 2 | Homo sapiens (human) | 0.8 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.0016 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 0.1743 | |
| Melanocortin receptor 5 | Homo sapiens (human) | 4.598 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.655 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 3.3935 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.26 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.2175 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 8.3173 | |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | 8.3173 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.0697 | |
| Transporter | Rattus norvegicus (Norway rat) | 0.26 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 10 (71.43) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Connor, TJ; Dredge, K; Harkin, A; Kelly, JP; Leonard, BE; McNamara, M; Redmond, A | 1 |
| Harkin, A; Kelly, JP; Leonard, BE; Nally, R | 1 |
| Cattell, D; Healy, D; Healy, H; Tranter, R | 1 |
| Hoenig, K; Kühn, KU; Maier, W; Quednow, BB; Stelzenmuelle, R; Wagner, M | 1 |
| Cryan, JF; Dalvi, A; Friedland, JC; Hirsch, BR; Jin, SH; Lucki, I; O'Leary, OF; Ouyang, M; Page, ME; Thomas, SA | 1 |
| Akgöz, S; Akkaya, C; Eker, SS; Kirli, S; Sarandöl, A | 1 |
| Akgoz, S; Akkaya, C; Kirli, S; Sarandol, A; Saygin Eker, S; Yazicioglu, B | 1 |
| Burrows, G; Jefferys, D | 1 |
| Itakura, C; Katayama, M; Niimi, K; Takahashi, E | 1 |
| Bootzin, E; Millan, MJ; O'Donnell, JM; Zhang, HT; Zhao, Z | 1 |
| Akkaya, C; Cangur, S; Eker, SS; Kirli, S; Sarandol, A | 1 |
| Eriksson, AC; Hägg, S; Hallbäck, I; Whiss, PA | 1 |
| Artigas, F; Bortolozzi, A; Ferrés-Coy, A; Fullana, MN; Meana, JJ; Ortega, JE; Paz, V; Ruiz-Bronchal, E | 1 |
| Hatano, M; Ikuta, T; Iwata, N; Kishi, T; Matsuda, Y; Okuya, M; Sakuma, K | 1 |
1 review(s) available for reboxetine and sertraline
| Article | Year |
|---|---|
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Topics: Adult; Amitriptyline; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Fluoxetine; Fluvoxamine; Humans; Mirtazapine; Network Meta-Analysis; Paroxetine; Randomized Controlled Trials as Topic; Reboxetine; Sertraline; Venlafaxine Hydrochloride; Vortioxetine | 2023 |
4 trial(s) available for reboxetine and sertraline
| Article | Year |
|---|---|
Functional effects of agents differentially selective to noradrenergic or serotonergic systems.
Topics: Adrenergic Uptake Inhibitors; Adult; Affect; Brain; Cross-Over Studies; Female; Humans; Male; Middle Aged; Morpholines; Personality Inventory; Quality of Life; Reboxetine; Receptors, Adrenergic; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Self-Assessment; Sertraline | 2002 |
Effects of serotonergic and noradrenergic antidepressants on auditory startle response in patients with major depression.
Topics: Acoustic Stimulation; Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Electrodes; Female; Habituation, Psychophysiologic; Humans; Male; Middle Aged; Morpholines; Psychiatric Status Rating Scales; Reboxetine; Reflex, Startle; Selective Serotonin Reuptake Inhibitors; Sertraline | 2004 |
[Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder].
Topics: Adolescent; Adult; Aged; Depressive Disorder; Female; Humans; Male; Middle Aged; Morpholines; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2005 |
A comparison of the efficacy and tolerability of reboxetine and sertraline versus venlafaxine in major depressive disorder: a randomized, open-labeled clinical trial.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Cyclohexanols; Depressive Disorder, Major; Drug Evaluation; Drug Interactions; Female; Humans; Male; Middle Aged; Morpholines; Reboxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Time Factors; Venlafaxine Hydrochloride | 2006 |
9 other study(ies) available for reboxetine and sertraline
| Article | Year |
|---|---|
Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amygdala; Analgesics; Animals; Antidepressive Agents; Body Temperature; Clonidine; Depression; Disease Models, Animal; Drug Therapy, Combination; Exploratory Behavior; Hydroxyindoleacetic Acid; Male; Morpholines; Motor Activity; Olfactory Bulb; Rats; Rats, Sprague-Dawley; Reboxetine; Serotonin Receptor Agonists; Sertraline; Swimming | 1999 |
Effects of reboxetine and sertraline treatments alone and in combination on the binding properties of cortical NMDA and beta1-adrenergic receptors in an animal model of depression.
Topics: Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Animals; Cerebral Cortex; Depressive Disorder; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Kynurenic Acid; Male; Morpholines; Neurons; Norepinephrine; Propanolamines; Rats; Rats, Sprague-Dawley; Reboxetine; Receptors, Adrenergic, beta-1; Receptors, N-Methyl-D-Aspartate; Serotonin; Sertraline | 2000 |
Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Desipramine; Dopamine beta-Hydroxylase; Droxidopa; Fluoxetine; Gene Deletion; Mice; Morpholines; Norepinephrine; Paroxetine; Reboxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Tail | 2004 |
Reversal of trichotillomania with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Morpholines; Piperazines; Quinolones; Reboxetine; Self Concept; Sertraline; Social Adjustment; Trichotillomania | 2008 |
Additive subthreshold dose effects of cannabinoid CB(1) receptor antagonist and selective serotonin reuptake inhibitor in antidepressant behavioral tests.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Male; Mice; Mice, Inbred CBA; Models, Animal; Morpholines; Motor Activity; Nomifensine; Piperidines; Pyrazoles; Reboxetine; Receptor, Cannabinoid, CB1; Rimonabant; Selective Serotonin Reuptake Inhibitors; Sertraline; Swimming | 2008 |
Association of changes in norepinephrine and serotonin transporter expression with the long-term behavioral effects of antidepressant drugs.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Brain; Cyclohexanols; Depression; Down-Regulation; Fenclonine; Male; Monoamine Oxidase Inhibitors; Morpholines; Norepinephrine Plasma Membrane Transport Proteins; Phenelzine; Protein Synthesis Inhibitors; Protriptyline; Rats; Rats, Sprague-Dawley; Reboxetine; RNA, Messenger; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Plasma Membrane Transport Proteins; Sertraline; Venlafaxine Hydrochloride | 2009 |
Are there differences between serotonergic, noradrenergic and dual acting antidepressants in the treatment of depressed women?
Topics: Adrenergic Uptake Inhibitors; Adult; Age Factors; Antidepressive Agents; Climacteric; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Middle Aged; Morpholines; Personality Inventory; Reboxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride; Young Adult | 2009 |
In vitro effects of serotonin and noradrenaline reuptake inhibitors on human platelet adhesion and coagulation.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Blood Coagulation; Blood Platelets; Citalopram; Cyclohexanols; Female; Fibrinogen; Humans; Male; Middle Aged; Morpholines; Norepinephrine; Platelet Adhesiveness; Reboxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline; Venlafaxine Hydrochloride; Young Adult | 2012 |
Selective Knockdown of TASK3 Potassium Channel in Monoamine Neurons: a New Therapeutic Approach for Depression.
Topics: Administration, Intranasal; Animals; Antidepressive Agents; Behavior, Animal; Depression; Down-Regulation; Gene Knockdown Techniques; Male; Mice, Inbred C57BL; Neurons; Norepinephrine; Potassium Channels; Reboxetine; RNA, Small Interfering; Serotonergic Neurons; Serotonin; Sertraline | 2019 |